Pfizer Inc.
NYSE:PFE
Products, Regulatory
Pfizer Inc Says EC Has Approved Xeljanz Prolonged-Release 11 Mg Once-Daily Tablets
Published: 08/20/2021 20:40 GMT
Pfizer Inc. (PFE) - Xeljanz® (tofacitinib Citrate) Receives Marketing Authorization in the European Union for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis.
Pfizer Inc - Two Formulations Were Approved, a Tablet and a New Oral Solution (weight-based Dosing).
Pfizer Inc - in Addition, Ec Has Approved Xeljanz Prolonged-release 11 Mg Once-daily Tablets.
Pfizer Inc - Two Formulations Were Approved, a Tablet and a New Oral Solution (weight-based Dosing).
Pfizer Inc - in Addition, Ec Has Approved Xeljanz Prolonged-release 11 Mg Once-daily Tablets.